Matches in SemOpenAlex for { <https://semopenalex.org/work/W2339676148> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2339676148 endingPage "4559" @default.
- W2339676148 startingPage "4559" @default.
- W2339676148 abstract "4559 Background: Androgen deprivation therapy (ADT) is effective for relapsed prostate cancer, but is rarely curative. The purpose of this trial was to determine the feasibility, toxicity and PSA response of chemotherapy and ADT for men with PSA relapse. Methods: Eligible men had a rising PSA and no metastases after prostatectomy and/or radiation for localized disease. Treatment consisted of four cycles of docetaxel (70 mg/M 2 ) every 21 days and estramustine 280 mg three times daily on days 1–5. After chemotherapy, goserelin acetate and bicalutamide 50 mg daily were prescribed for 15 months. Results: Sixty-two patients were enrolled at four institutions: median age 65 (range 49–78), median PSA 3.01 ng/mL (range 0.08–47.04), 24% Gleason 8–10. A complete PSA response (CR) was defined as PSA at or below assay-specific lower limit (0.01–0.2 ng/mL). The proportion of patients with CR after chemotherapy, after ADT and at one year off ADT was 53%, 63% and 36%. Testosterone was > 100 ng/dL (median 250 ng/dL) one year off ADT in 97%. Patients with a PSA < 3.0 ng/mL had a significantly longer time to progression (p-value 0.0002). At the time of last follow-up 24/56 (43%) who are at least one year off ADT have not progressed. Median TTP is 34 months from treatment initiation (maximum 74 months free from progression). Toxicity was manageable with no toxic deaths: there were 4 thromboses on chemotherapy and 38% of cycles were associated with grade III/IV neutropenia with 5 cases of documented infections. Conclusion: Chemotherapy prior to hormone therapy was feasible for early prostate cancer relapse. Forty-three percent of men who are at least one year off ADT with recovered testosterone have not progressed. This approach is being tested in a randomized trial with investigation of predictors of response. No significant financial relationships to disclose." @default.
- W2339676148 created "2016-06-24" @default.
- W2339676148 creator A5017334876 @default.
- W2339676148 creator A5023517416 @default.
- W2339676148 creator A5043769628 @default.
- W2339676148 creator A5058565414 @default.
- W2339676148 creator A5066816851 @default.
- W2339676148 creator A5089516753 @default.
- W2339676148 date "2006-06-20" @default.
- W2339676148 modified "2023-10-14" @default.
- W2339676148 title "Chemo-hormonal therapy for biochemical progression of prostate cancer" @default.
- W2339676148 doi "https://doi.org/10.1200/jco.2006.24.18_suppl.4559" @default.
- W2339676148 hasPublicationYear "2006" @default.
- W2339676148 type Work @default.
- W2339676148 sameAs 2339676148 @default.
- W2339676148 citedByCount "0" @default.
- W2339676148 crossrefType "journal-article" @default.
- W2339676148 hasAuthorship W2339676148A5017334876 @default.
- W2339676148 hasAuthorship W2339676148A5023517416 @default.
- W2339676148 hasAuthorship W2339676148A5043769628 @default.
- W2339676148 hasAuthorship W2339676148A5058565414 @default.
- W2339676148 hasAuthorship W2339676148A5066816851 @default.
- W2339676148 hasAuthorship W2339676148A5089516753 @default.
- W2339676148 hasConcept C121608353 @default.
- W2339676148 hasConcept C126322002 @default.
- W2339676148 hasConcept C126894567 @default.
- W2339676148 hasConcept C141071460 @default.
- W2339676148 hasConcept C143998085 @default.
- W2339676148 hasConcept C2776694085 @default.
- W2339676148 hasConcept C2777899217 @default.
- W2339676148 hasConcept C2778043895 @default.
- W2339676148 hasConcept C2778311097 @default.
- W2339676148 hasConcept C2779466945 @default.
- W2339676148 hasConcept C2780192828 @default.
- W2339676148 hasConcept C2780962315 @default.
- W2339676148 hasConcept C2781190966 @default.
- W2339676148 hasConcept C61367390 @default.
- W2339676148 hasConcept C71924100 @default.
- W2339676148 hasConceptScore W2339676148C121608353 @default.
- W2339676148 hasConceptScore W2339676148C126322002 @default.
- W2339676148 hasConceptScore W2339676148C126894567 @default.
- W2339676148 hasConceptScore W2339676148C141071460 @default.
- W2339676148 hasConceptScore W2339676148C143998085 @default.
- W2339676148 hasConceptScore W2339676148C2776694085 @default.
- W2339676148 hasConceptScore W2339676148C2777899217 @default.
- W2339676148 hasConceptScore W2339676148C2778043895 @default.
- W2339676148 hasConceptScore W2339676148C2778311097 @default.
- W2339676148 hasConceptScore W2339676148C2779466945 @default.
- W2339676148 hasConceptScore W2339676148C2780192828 @default.
- W2339676148 hasConceptScore W2339676148C2780962315 @default.
- W2339676148 hasConceptScore W2339676148C2781190966 @default.
- W2339676148 hasConceptScore W2339676148C61367390 @default.
- W2339676148 hasConceptScore W2339676148C71924100 @default.
- W2339676148 hasIssue "18_suppl" @default.
- W2339676148 hasLocation W23396761481 @default.
- W2339676148 hasOpenAccess W2339676148 @default.
- W2339676148 hasPrimaryLocation W23396761481 @default.
- W2339676148 hasRelatedWork W1562127342 @default.
- W2339676148 hasRelatedWork W1971336065 @default.
- W2339676148 hasRelatedWork W2094355087 @default.
- W2339676148 hasRelatedWork W2299690226 @default.
- W2339676148 hasRelatedWork W2600999145 @default.
- W2339676148 hasRelatedWork W2601533899 @default.
- W2339676148 hasRelatedWork W2907060458 @default.
- W2339676148 hasRelatedWork W2982156914 @default.
- W2339676148 hasRelatedWork W4297472852 @default.
- W2339676148 hasRelatedWork W4319748405 @default.
- W2339676148 hasVolume "24" @default.
- W2339676148 isParatext "false" @default.
- W2339676148 isRetracted "false" @default.
- W2339676148 magId "2339676148" @default.
- W2339676148 workType "article" @default.